Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL092 + pembrolizumab versus pembrolizumab in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma
2023-506308-24-00Phase 3Authorised
- Sponsor
- Exelixis, Inc.
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing XL092 + pembrolizumab with Pembrolizumab (2 arms). Primary endpoint: Progression-free survival. Planned start May 2024; status: authorised.
02
Drugs
pembrolizumabzanzalintinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-506308-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506308-24-00.